一种新型抗逆转录病毒药物——Maraviroc

• 作 者: 徐雨 姚瑜
• 机 构: 中国医药集团四川抗菌素工业研究所,
• 出 处: 国外医药(抗生素分册)
• 发表日期: 2009年01期
• 关键词: 抗逆转录病毒 趋向性 趋化因子受体 共受体阻滞剂 V3环序列 商品名 受体阻滞剂 辉瑞制药 潜在作用 协同受体

Maraviroc(又名UK-427857,由辉瑞制药研发,在美国以外使用商品名Selzentry或Celsentri)是获得FDA和EMEA批准的首个新型口服HIV-1抑制剂。该药物被寄望于只对携带R5病毒的患者(即HIV-1感染者中的1个亚群)有效。目前,有关该药物的广泛使用主要面临2个问题:一是缺乏简便而适用的R5病毒特异性检测方法,即趋向性测试;其次是对于R5和X4病毒在感染期间的动力学研究还不够。本文探讨了人们应用目前可用的测试法时所面临的困难,以及备选测试方法的潜在作用。

Maraviroc (aka UK-427857, developed by Pfizer and used outside the United States under the trade name Selzentry or Celsentri) is the first novel oral HIV-1 inhibitor approved by the FDA and EMEA. The drug is expected to be effective only for patients carrying the R5 virus (ie, one of the HIV-1 infected individuals). At present, there are mainly two problems related to the widespread use of this drug: one is the lack of a simple and applicable R5 virus-specific test, that is, a trend test; and the second is that the kinetics of R5 and X4 viruses during infection is not sufficient. This article explores the difficulties people face when applying currently available test methods and the potential role of alternative test methods.